Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

DRI Healthcare Trust (T:DHT.UN)

Business Focus: N/A

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for DHT within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Nov 30, 2021 16:40 ET
DRI Healthcare Trust Comments on Extension of Review Period for pacritinib
TORONTO, Nov. 30, 2021 /CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI" or "the Trust") today announced that it has been notified by CTI BioPharma Corp. (CTI) that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application for pacritinib for the treatment of adult Myelofibrosis patients with severe thrombocytopenia. According to CTI, the PDUFA date has been extended by three months to February 28, 2022. Approval of pacritinib by the FDA is a condition to the acquisition by DRI of a tiered royalty on pacritinib, as announced on August
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
--
--
--
Price to Sales - TTM
--
--
--
Price to Book - most recent quarter
--
--
--
Price to Cash Flow per share - TTM
--
--
--
Price to Free Cash Flow per share - TTM
--
--
--
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Nov 15, 202100
Oct 31, 202100
Oct 15, 202100
See Short Report

Business Summary

Sector:  N/A Industry:  N/A

See business summary

 

Twitter

Search (past week) for $DHT.UN